Galderma Enrolls Patients in Study of Chronic Pruritus of Unknown Origin Treatment

MT Newswires · 3d ago
08:46 AM EST, 12/11/2025 (MT Newswires) -- Galderma Group (GALD.SW) started enrolling patients for its mid-stage study to evaluate monoclonal antibody nemolizumab for the treatment of chronic pruritus of unknown origin, or CPUO. The Swiss dermatology company will assess the therapeutic potential of nemolizumab in adults in the randomized, double-blind, placebo-controlled phase II study in the US, according to a Thursday release. Nemolizumab targets the IL-31 receptor alpha, a neuroimmune cytokine that drives itch, the main symptom of CPUO.